Nathalie Rufer Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Switzerland
1 protocol

Pedro Romero Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
3 protocols

Daniel Speiser Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
1 protocol

Petra Baumgaertner Ludwig Center for Cancer Research (LICR), Lausanne Branch, Switzerland
1 protocol

Michael Hebeisen
  • Department of Oncology, Lausanne University Hospital Center (CHUV) and University of Lausanne, Switzerland
Research focus
  • Immunology
  • 1 Author merit


Ph.D. in Developmental Biology and Cancer Genetics, McGill University, Department of Biology, Montréal, Canada, 2008

Current position

Project Leader in cancer immunotherapy, Department of Fundamental Oncology, Ludwig Institute for Cancer Research (LICR) and University Hospital of Lausanne (CHUV),  Epalinges, Switzerland


  1. Hebeisen, M., Allard, M., Gannon, P. O., Schmidt, J., Speiser, D. E. and Rufer, N. (2015). Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens. Front Immunol 6: 582.

  2. Gannon, P. O., Wieckowski, S., Baumgaertner, P., Hebeisen, M., Allard, M., Speiser, D. E. and Rufer, N. (2015). Quantitative TCR:pMHC Dissociation Rate Assessment by NTAmers Reveals Antimelanoma T Cell Repertoires Enriched for High Functional Competence. J Immunol 195(1): 356-366.

  3. Hebeisen, M., Schmidt, J., Guillaume, P., Baumgaertner, P., Speiser, D. E., Luescher, I. and Rufer, N. (2015). Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells. Cancer Res 75(10): 1983-1991.

  4. Dudda, J. C., Salaun, B., Ji, Y., Palmer, D. C., Monnot, G. C., Merck, E., Boudousquie, C., Utzschneider, D. T., Escobar, T. M., Perret, R., Muljo, S. A., Hebeisen, M., Rufer, N., Zehn, D., Donda, A., Restifo, N. P., Held, W., Gattinoni, L. and Romero, P. (2013). MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. Immunity 38(4): 742-753.

  5. Hebeisen, M., Oberle, S. G., Presotto, D., Speiser, D. E., Zehn, D. and Rufer, N. (2013). Molecular insights for optimizing T cell receptor specificity against cancer. Front Immunol 4: 154.

  6. Hebeisen, M., Baitsch, L., Presotto, D., Baumgaertner, P., Romero, P., Michielin, O., Speiser, D. E. and Rufer, N. (2013). SHP-1 phosphatase activity counteracts increased T cell receptor affinity. J Clin Invest 123(3): 1044-1056.

  7. Irving, M., Zoete, V., Hebeisen, M., Schmid, D., Baumgartner, P., Guillaume, P., Romero, P., Speiser, D., Luescher, I., Rufer, N. and Michielin, O. (2012). Interplay between T cell receptor binding kinetics and the level of cognate peptide presented by major histocompatibility complexes governs CD8+ T cell responsiveness. J Biol Chem 287(27): 23068-23078.

  8. Hebeisen, M., Rufer, N., Oberle, S., Speiser, D.E. and Zehn, D. (2012). Signaling mechanisms that balance anti-viral, auto-reactive and anti-tumor potential of low affinity T cells. J Clin Cell Immunol S12:003

  9. Schmid, D. A., Irving, M. B., Posevitz, V., Hebeisen, M., Posevitz-Fejfar, A., Sarria, J. C., Gomez-Eerland, R., Thome, M., Schumacher, T. N., Romero, P., Speiser, D. E., Zoete, V., Michielin, O. and Rufer, N. (2010). Evidence for a TCR affinity threshold delimiting maximal CD8 T cell function. J Immunol 184(9): 4936-4946.

  10. Hebeisen, M., Drysdale, J. and Roy, R. (2008). Suppressors of the cdc-25.1(gf)-associated intestinal hyperplasia reveal important maternal roles for prp-8 and a subset of splicing factors in C. elegans. RNA 14(12): 2618-2633.

  11. Hebeisen, M. and Roy, R. (2008). CDC-25.1 stability is regulated by distinct domains to restrict cell division during embryogenesis in C. elegans. Development 135(7): 1259-1269.

1 Protocol published
Chromium-51 (51Cr) Release Assay to Assess Human T Cells for Functional Avidity and Tumor Cell Recognition
Authors:  Petra Baumgaertner, Daniel E. Speiser, Pedro Romero, Nathalie Rufer and Michael Hebeisen, date: 08/20/2016, view: 13424, Q&A: 0
Cytotoxic CD8+ T cells are able to specifically recognize and kill target cells through specific interaction between their T cell receptors (TCRs) and small immunogenic peptides (antigens) presented by major histocompatibility complex ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.